重组集成干扰素α体外抗病毒的药效学研究

目的：观察一种新型重组集成干扰素α(NIFN con α)对流感病毒甲型和乙型、单纯疱疹病毒Ⅰ型和Ⅱ型、柯萨奇病毒B1和B3的抑制作用。方法：应用细胞病变抑制法，以已上市的重组集成干扰素α(干复津)及干扰素α作为阳性对照，观察不同浓度的NIFN con α对不同病毒感染绿猴肾细胞(Vero)和狗肾细胞(MDCK)的抑制作用。结果：NIFN con α对MDCK细胞和Vero细胞的TD50分别为(>250±0)μg/ml和(>192±0)μg/ml。对单纯疱疹Ⅰ型和Ⅱ型病毒的IC50分别是(2.8×10-4±8.5×10-5) 和(1.8×10-4±8.5×10-5)μg/ml；对柯萨奇病毒B1和B3的IC50分别是(8.8×10-8±1.4×10-8)和(1.5×10-7±4.2×10-8)μg/ml，抑制流感病毒甲型和乙型的IC50分别是(2.5×10-2±1.2×10-2)和(＞10±0)μg/ml。结论：NIFN con α与干复津一样对单纯疱疹病毒、柯萨奇病毒和流感病毒均具有明显的抑制作用，与干扰素α相比，对流感病毒的抑制作用较弱，但对单纯疱疹病毒和柯萨奇病毒的抑制作用优于干扰素α。

Inhibitory effects of recombinant consensus interferon α on different viruses in vitro

To investigate the antiviral activity of one of the new recombinant consensus interferon α (NIFN con　α) in vitro. Methods: The cytopathic effect inhibition assay was applied in this study to investigate the antiviral activity of this drug as well as the other IFN con α (Infergen) and IFN α as positive control. Vero cells and MDCK cells were infected by different viruses respectively and were cultured with serial dilutions of NIFN con α. Results: The TD50 of NIFN con α for MDCK cells and Vero cells was (＞250±0)μg/ml and >192±0?μg/ml， respectively. The IC50 of NIFN con α for Herpes virus type 1 and type 2 was (2.8×10-4±8.5×10-5) and (1.8×10-4±8.5×10-5) μg/ml, respectively, for coxsackie virus B1 and B3 was (8.8×10-8±1.4×10-8) and (1.5×10-7±4.2×10-8) μg/ml, respectively and for influenza virus A and B was (2.5×10-2±1.2×10-2) and (＞10±0)μg/ml, respectively. Conclusion: The new drug has similar antiviral activities with Infergen, and compare with interferon α, it has more effective antiviral activities for HSV and coxsackie virus except for influenza viruses.